Acacia Pharma is a commercially driven hospital pharmaceutical group focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients.
The Group has identified important and commercially attractive unmet needs in nausea and vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
Acacia Pharma has retained rights to commercialise its product candidates in all territories and plans to sell them directly in the US through its own commercial operations. Acacia Pharma intends to establish licensing and/or distribution agreements with selected pharmaceutical partners outside the US.
The Group’s pipeline has been generated by repurposing drugs already marketed for other uses that have biological properties appropriate for their development as patented products for surgical and cancer patients.
Acacia Pharma has a management team with extensive experience in the discovery, development and commercialisation of hospital pharmaceutical products and in drug repurposing.
The Group was founded in 2007 and is based in Cambridge, UK with US operations in Indianapolis.